Tag Archives: biotechnology law

Report From Bio – Everyone Into The Pool!

I have been hearing about “patent pools” for biotech patents for years, but Kristen Neuman made it much more real at a Break-Out Session on Diagnostics and Personalized Medicine at the BIO International Convention in DC today (6/29/11). The session … Continue reading

Posted in USPTO Practice and Policy | Tagged , , , , , , , , , | Leave a comment

Supreme Court Grants Cert. In Caraco

Today (June 27, 2010), the Supreme Court granted cert. in yet another patent appeal, Caraco Pharm. Labs., Ltd., v. Novo Nordisk, (Supreme Ct. 10-844). Earlier this month, I did an extensive post on the decision below, in which the Fed. … Continue reading

Posted in Hatch-Waxman | Tagged , , , , , , , , , , , , | Leave a comment

Supreme Court Grants Cert. In Mayo v. Prometheus

Today, in what may be an ominous turn for biotech IP law, the Supreme Court granted cert. for the second time in Mayo Collaborative Services v. Prometheus Labs., Inc, Supreme Court No. 10-1150. Post-Bilski, the Supreme Court granted cert., vacated … Continue reading

Posted in Patent Eligible Subject Matter | Tagged , , , , , , , , , | Leave a comment

Caraco – The Little Counterclaim That Could?

I normally try to steer clear of issues raised in Hatch-Waxman litigation between the “innovators” and the “generics,” unless it raises specific points of patent law of general interest – there is just so much of it, and other blogs … Continue reading

Posted in Hatch-Waxman | Tagged , , , , , , , , , , , , , , | 2 Comments